Filing Flows

Filing Flows › Companies › PTC Therapeutics › Cash flow

PTC Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$28.0M in Q3 2026 · $2.1M over twelve months

Operating cash flow−$25.3M
Capital spending−$2.7M
Free cash flow−$28.0M

Analysis

In Q3 2026, PTC Therapeutics generated −$25.3M of operating cash flow and spent $2.7M on capital projects, leaving free cash flow of −$28.0M. That is $41.8M more than in Q3 2025 (−$69.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $10.5M; the largest uses were other investing ($616M), capital spending ($8.4M), net borrowing (+) / repaid (−) ($3.0M); besides operations, cash came from other financing ($366M), shares issued ($84.4M); the cash balance fell by $161M.

Operating cash flow was −$25.3M against net income of −$51.7M. The largest differences: stock-based pay +$23.8M, inventory −$18.1M, depreciation & amortization +$16.8M.

Free cash flow

PTC Therapeutics: free cash flow by quarterPTC Therapeutics: free cash flow by quarter−$33.8MQ4 2024$868MQ1 2025−$59.6MQ2 2025−$69.8MQ3 2025−$36.6MQ4 2025−$60.2MQ1 2026$127MQ2 2026−$28.0MQ3 2026
Operating cash flow less capital spending.
PTC Therapeutics: operating cash flow against capital spendingPTC Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$30.0M$3.8MQ4 2024$870M$1.7MQ1 2025−$58.3M$1.2MQ2 2025−$66.3M$3.5MQ3 2025−$34.3M$2.4MQ4 2025−$59.0M$1.2MQ1 2026$129M$2.2MQ2 2026−$25.3M$2.7MQ3 2026
Latest (Q3 2026): Operating cash flow −$25.3M, Capital spending $2.7M.

Capital allocation, year by year

PTC Therapeutics: where the cash came from (up) and went (down), by fiscal yearPTC Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$251MFY2021: Net borrowing −$2.2MFY2021: Shares issued $17.3MFY2021: Capital spending −$28.2M$17.3MFY2021FY2022: Operating cash flow −$357MFY2022: Net borrowing $149MFY2022: Shares issued $14.6MFY2022: Capital spending −$32.0M$163MFY2022FY2023: Operating cash flow −$158MFY2023: Net borrowing −$301MFY2023: Shares issued $24.0MFY2023: Capital spending −$28.4M$24.0MFY2023FY2024: Operating cash flow −$108MFY2024: Net borrowing −$1.5MFY2024: Shares issued $28.6MFY2024: Asset sales $28.1MFY2024: Capital spending −$6.5M$56.6MFY2024FY2025: Operating cash flow $711MFY2025: Net borrowing −$1.6MFY2025: Shares issued $93.1MFY2025: Asset sales $70KFY2025: Capital spending −$8.9M$804MFY2025
Over these 5 years operating cash flow totalled −$163M; the largest uses were operating cash flow ($874M) and net borrowing ($307M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.1B
Debt$592M
Net cash$1.5B
Due within a year$55.5M
Cash runwaymore than 10 years

PTC Therapeutics is burning cash: its operations consume cash, a free cash flow of −$112M a year at the current rate against $2.1B of cash and investments: a runway of more than ten years at that rate; $55.5M of debt also comes due within a year, which the cash covers before any new financing.

Where the cash came from and went

PTC Therapeutics: sources (+) and uses (−) of cash, Q3 2026PTC Therapeutics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$541MOther investing−$440MOther financing−$78.6MOperating cash flow−$25.3MShares issued$5.3MCapital spending−$2.7MExchange rates−$38K
PTC Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026PTC Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$616MOther financing$366MCash drawn (+) / kept (−)$161MShares issued$84.4MOperating cash flow$10.5MCapital spending−$8.4MExchange rates$5.7MNet borrowing (+) / repaid (−)−$3.0M

From profit to cash

PTC Therapeutics: net income to operating cash flow, Q3 2026PTC Therapeutics: net income to operating cash flow, Q3 2026Net income−$51.7MDepreciation & amortization$16.8MStock-based pay$23.8MReceivables$42KInventory−$18.1MPayables$10.7MDeferred revenue$811KPrepaid and other assets−$4.7MOther liabilities−$2.7MOperating cash flow−$25.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$25.3M−$2.7M$5.3M$541M−$28.0M
Q2 2026$129M−$2.2M$13.2M−$216M$127M
Q1 2026−$59.0M−$1.2M$6.4M$148M−$60.2M
Q4 2025−$34.3M−$2.4M$59.4M−$312M−$36.6M
Q3 2025−$66.3M−$3.5M$16.8M$347M−$69.8M
Q2 2025−$58.3M−$1.2M$1.1M$463M−$59.6M
Q1 2025$870M−$1.7M$15.8M−$701M$868M
Q4 2024−$30.0M−$3.8M$23.2M−$256M−$33.8M

PTC Therapeutics: income statement and cash flow

PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%. The chart follows the revenue to costs, profit and cash.

PTC Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.